Efficacy of Achieving Early Target Trough Levels of Tacrolimus Using CYP3A5 Guided Dosing Versus Weight-based Dosing in a Multi-ethnic Population of Kidney Transplant Recipients in Singapore
Kidney Transplant Rejection, Kidney Transplant; Complications

About this trial
This is an interventional treatment trial for Kidney Transplant Rejection focused on measuring kidney transplant, tacrolimus, CYP3A5, Pharmacogenomics
Eligibility Criteria
Inclusion Criteria:
- On follow up at SGH between the ages of 21 and 75 years old who had received or are scheduled to receive a living donor renal transplant between January 2016 to January 2023
- Has to receive tacrolimus (FK) (Prograf®; Astellas Pharma, Singapore), mycophenolic acid (MPA) (Cellcept®; Roche, Basel, Switzerland or Myfortic®; Novartis Pharma AG, Basel, Switzerland) and prednisolone as triple immunosuppressive drug maintenance regimen
Exclusion Criteria:
- Planned to be initiated on non-standard doses of tacrolimus (e.g. planned to initiate on sub-therapeutic doses of tacrolimus)
- Evidence of active liver disease or gastrointestinal disorder that might interfere with the ability to absorb oral medication
- Contraindications to tacrolimus (FK) - e.g. hypersensitivity
- Takes concurrent medications which are known to severely interact with FK (e.g. verapamil, azoles, rifampicin, erythromycin or clarithromycin
Sites / Locations
- Singapore General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Intervention genotyping group
Historical Control Group
Patients who are scheduled to receive renal transplant from a living donor between January 2021 to January 2023. They will be assigned to receive the initial CYP3A5 genotype-based tacrolimus (FK) dose as determined by their CYP3A5 genotype. CYP3A5 expresser (extensive or intermediate metabolizer) - 0.20mg/kg CYP3A5 non-expresser (poor metabolizer) - 0.15mg/kg The starting dose of the intervention arm will be reviewed for every 10 patients recruited based on the drug levels achieved.
Patients who received renal transplant from a living donor between January 2016 - December 2020 and received standard weight-based dosing of tacrolimus